# Candid Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/candid-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.candidrx.com
- Total disclosed funding: $206M
- Latest round: Series B (Aug 19, 2024)
- Investors on record: 19

## About

Founded in 2024 and based in California, US, Candid Therapeutics, Inc. is a biotechnology company that offers therapies for the treatment of a range of immunological conditions. In March 2026, Candid Therapeutics, Inc. raised USD 505 million in venture funding from new investors Venrock Healthcare Capital Partners, RA Capital Management, Janus Henderson Investors, Viking Global Investors, Cormorant Asset Management, Vivo Capital. Returning investors VenBio, Foresite Capital, Soleus Capital Management, TCG Crossover Management and other unspecified investors also participated in the round. As of 2024, the company is being led by its CEO, Ken Song, CMO, Tim Lu, CFO, Arvind Kush, and CTO, Bernie Huyghe.

Candid Therapeutics develops therapies for autoimmune diseases, aiming to provide effective treatments through T-cell engager antibodies. Their approach targets autoreactive B-cells by leveraging T-cells that penetrate deeper and provide more durable B-cell depletion compared to traditional antibody treatments like Rituxan® and avoids the complexities and costs associated with cell therapies.

## Funding rounds

- Series B, Aug 19, 2024, $206M — OrbiMed Advisors, Polaris Partners, Venrock, Qiming Venture Partners, Third Rock Ventures, Fidelity Investments, Foresite Capital, Redmile Group, VenBio, Franklin Templeton, Fairmount Funds Management, Two River, LifeSci Partners, Samsara BioCapital, Soleus Capital, TCG Crossover Management, Vidavo Ventures, Boxer Capital, Mirae Asset Capital Life Science

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- VenBio (https://capitalatlas.ai/funds/venbio) — Series B
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series B
- Fairmount Funds Management — Series B
- Two River (https://capitalatlas.ai/funds/two-river) — Series B
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B
- Vidavo Ventures (https://capitalatlas.ai/funds/vidavo-ventures) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- Mirae Asset Capital Life Science (https://capitalatlas.ai/funds/mirae-asset-capital-life-science) — Series B